Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Enrolling by invitation × Afatinib × Clear all

Phase

Status

Completed 88 Unknown 17 Terminated 15 Recruiting 12 Withdrawn 6 Active not recruiting 5 Approved for marketing 3 Suspended 1 Not yet recruiting 1 No longer available 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 7 Educational Status 7 Interviews as Topic 6 Fluorodeoxyglucose F18 5 Drug Therapy 5 Cisplatin 5 Chemoradiotherapy 5 Surveys and Questionnaires 4 Standard of Care 4 Radiotherapy 4 Observation 4 Fluorouracil 4 Carboplatin 4 Blood Specimen Collection 4 lenvatinib 3 camrelizumab 3 Surgical Procedures, Operative 3 S 1 (combination) 3 Nivolumab 3 Methods 3 Lenalidomide 3 Early Intervention, Educational 3 Dexamethasone 3 Cyclophosphamide 3 Capecitabine 3 Biopsy 3 130-nm albumin-bound paclitaxel 3 venetoclax 2 sintilimab 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06759857 2025-01-06

FHND9041

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡